Synergy-Outcomes Study
Metabolic “Fatty Liver” Disease
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide (ZEPBOUND®) can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as “fatty liver disease.”
The study will enroll adults who have MASLD (“fatty liver disease”) based on non-invasive tests (no liver biopsy required at screening), which indicate they are more likely to develop serious liver-related complications. Participants will be randomly assigned to receive either retatrutide (an investigational triple agonist of the GLP-1, GIP and glucagon receptors), tirzepatide (an approved dual agonist of GLP-1 and GIP receptors) or placebo. At the end of the placebo-controlled portion of this study, all eligible participants will have the option to receive retatrutide or tirzepatide as part of a 2-year open-label extension study.
If you are considering participating in this clinical research study, please complete the form and someone from our team will reach out to you.